Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate
New York
|
February 24, 2023 08:01 AM Eastern Standard Time
Eloxx Pharmaceuticals president and CEO Sumit Aggarwal joins Proactive's Natalie Stoberman to discuss the latest update on the clinical study for its lead investigational product candidate ELX-02.
Aggarwal said the first batch of patients has now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Up to eight Alport syndrome patients with nonsense mutations in the COL4 gene will be dosed for two months with a three-month follow-up.
With this timeline, the company is expected to remain on track to deliver topline clinical results from this trial in the first half of 2023.
Contact Details
Proactive US
+1 347-449-0879
